

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number  
**WO 03/066097 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 39/395**

(21) International Application Number: **PCT/EP03/01229**

(22) International Filing Date: 7 February 2003 (07.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

02075544.3	8 February 2002 (08.02.2002)	EP
02077742.1	9 July 2002 (09.07.2002)	EP
03100148.0	24 January 2003 (24.01.2003)	EP

(71) Applicants (*for all designated States except US*):  
**VLAAMS INTERUNIVERSITAIR INSTITUUT  
VOOR BIOTECHNOLOGIE VZW** [BE/BE]; Rijviss-  
chestraat 120, B-9052 Zwijnaarde (BE). **D. COLLEN  
RESEARCH FOUNDATION VZW** [BE/BE]; Onder-  
wijs & Navorsing, Campus Gasthuisberg, K.U. Leuven,  
Herestraat 49, B-3000 Leuven (BE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CARMELIET,  
Peter** [BE/BE]; Sappelenbos 10, B-3052 Blanden (BE).  
**MOONS, Lieve** [BE/BE]; Beningstraat 25, B-2230  
Herselt (BE).

(74) Agent: **BRANTS, Johan, Philippe, Emile**; De Clercq,  
Brants & Partners cv, E. Gevaertdreef 10a, B-9830 Sint-  
Martens-Latem (BE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished  
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **A NOVEL TARGET TO INHIBIT ANGIOGENESIS**

(57) Abstract: The invention relates to the field of angiogenesis. In particular the invention relates to the use of molecules binding to prominin-1 that can be used for the manufacture of a medicament to prevent pathological angiogenesis.



**WO 03/066097 A2**



## A novel target to inhibit angiogenesis

### Field of the invention

The invention relates to the field of angiogenesis. In particular the invention relates to the use of molecules binding to prominin-1 that can be used for the manufacture of a medicament to prevent pathological angiogenesis.

### Background of the invention

Prominin-1 (PROM-1), also called AC133 or recently designed CD133 (National Center for Biotechnology, 2000), is a rather novel human hematopoietic stem cell antigen <sup>1</sup> of unknown physiological or pathological function. Prominin-1-antigen was first detected on CD34<sup>bright</sup> hematopoietic stem cells <sup>2</sup> and has since been widely used to facilitate the analysis and isolation of hematopoietic and primitive cells <sup>3-5</sup>. Only few prominin-1<sup>+</sup> cells do not coexpress CD34: these cells are very small and define a population of unknown delineation <sup>6</sup>. In acute myeloid leukemias, PROM-1 expression is often but not always associated with CD34 expression <sup>7,8</sup>. Prominin-1 is also found on acute lymphoid leukemia blasts and on a subset of CD34<sup>+</sup> B-cell precursors <sup>9</sup>. Flow cytometry analyses of a wide panel of human cell lines showed that only retinoblastoma and teratocarcinoma cell lines express prominin-1<sup>10</sup>. More recently, it was shown that endothelial progenitor cells co-express PROM-1 antigen and the endothelial cell-specific receptor kinase-inert domain-containing acceptor (KDR) in subpopulations of CD34<sup>+</sup> cells derived from fetal liver, bone marrow, cord blood and peripheral blood <sup>11,12</sup>. Recently, human central nervous system stem cells were also reported to express prominin-1-antigen <sup>13</sup>. A characteristic feature of this protein is its rapid down-regulation during cell differentiation <sup>12,14</sup>, which makes it a unique cell surface marker for the identification and isolation of stem cells and progenitor cells. Human PROM-1 antigen is a glycoprotein of 120 KD and contains an extracellular N-terminus, two extracellular loops, five transmembrane domains, two small cysteine-rich cytoplasmic loops and a cytoplasmic C terminus <sup>1</sup>. Recently a novel isoform of human PROM-1 with a 27 basepair deletion has been described <sup>15</sup>. A structural and sequence-related protein, was identified as the mouse orthologue of human PROM-1 <sup>14</sup>. The 5-transmembrane structure appears phylogenetically conserved from mammals to zebrafish and in fruit flies and nematodes <sup>16,17</sup>. Murine prominin-1, which has a 65% amino acid homology

with human PROM-1 also exists in two isoforms. The short human and murine prominin isoform both encode proteins that lack a 9-amino acid segment at the same location in the N-terminal extracellular region just proximal to the first transmembrane domain<sup>15,18,19</sup>. Although human PROM-1 has been used as a cell surface marker to identify and isolate certain stem cell and progenitor cell populations, the molecular mechanism of how this protein functions remain unclear. The possible role of PROM-1 in hematopoiesis and vasculogenesis in the developing embryo and, after birth, in angiogenesis, postnatal vasculogenesis and hematopoietic stem cell trafficking, remains largely unknown. To study in detail the *in vivo* role of PROM-1 in the present invention PROM-1 deficient mice were generated. It was surprisingly found that PROM-1 has a key role in pathological angiogenesis and that inhibitors of PROM-1 can be used in therapeutic strategies to inhibit blood vessel formation in various pathological disorders.

#### Aims and detailed description of the invention

The "hemangioblast" is a putative progenitor cell that has the potential to form either endothelial or hematopoietic cells. It exists during embryogenesis in the blood island region of the yolk sac<sup>20</sup>, which is therefore the earliest site of hematopoiesis and vasculogenesis. Until recently, vasculogenesis has been thought to be restricted to the yolk sac and the early embryogenesis. However, novel observations have revealed in adulthood a situation consistent with vasculogenesis: endothelial cells derived from angioblasts or "hemangioblasts" previously isolated from peripheral blood or bone marrow are incorporated into sites of neovascularization in physiological and pathological conditions<sup>21-25</sup>. In addition, the number of these endothelial cell progenitors increases in the peripheral blood during tissue ischemia or following the administration of VEGF or GM-CSF, a cytokine known to induce mobilization of hematopoietic stem cells from the bone marrow into the peripheral blood<sup>24,25</sup>. Recent studies in humans, dogs, rats, rabbits and mice have indeed indicated the presence of endothelial precursor cells (EPCs) in bone marrow and peripheral blood during adult life which can be mobilized and incorporated into newly formed vessels or are involved in endothelialization of implants<sup>23,26-32</sup>. Interestingly, in all these experiments, endothelial cell progenitors are isolated together with other hematopoietic stem cells by using antibodies directed against hematopoietic stem cell antigens. PROM-1 is expressed on lineage non-committed stem and progenitor cells but not on mature peripheral blood cells and umbilical vein derived endothelial cells<sup>2</sup>. CD34<sup>+</sup> cells co-

expressing VEGFR-2 and PROM-1, have been isolated from peripheral blood, cord blood, fetal liver and bone marrow. When grown in the presence of VEGF and FGF-2 or the cytokine stem cell growth factor (SCGF), these cells give rise to endothelial cells, thus suggesting that this subset of CD34<sup>+</sup>, VEGFR-2<sup>+</sup> & CD133<sup>+</sup> cells may play a role in neovasculogenesis<sup>3,5,11</sup>. The present invention uses a transgenic mouse deficient in PROM-1 to study the involvement of PROM-1 in several pathological models of angiogenesis. For the sake of clarity the nucleotide sequence of human prominin-1 is designated here as SEQ ID NO: 1 and the amino acid sequence of human prominin-1 is designated as SEQ ID NO: 2. The present invention shows that inhibitors of prominin-1 can be used in therapeutic applications for the prevention of pathological angiogenesis.

Thus the invention provides in one embodiment the use of a molecule which comprises a region specifically binding to prominin-1 (SEQ ID NO: 2) or nucleic acids encoding prominin-1 (SEQ ID NO: 1), for the manufacture of a medicament to treat pathological angiogenesis.

According to the invention molecules that comprise a region specifically binding to prominin-1 or nucleic acids encoding prominin-1 which can be used for the manufacture of a medicament to treat pathological angiogenesis can be chosen from the list comprising an antibody or any fragment thereof binding to prominin-1, a (synthetic) peptide, a protein, a small molecule specifically binding to prominin-1 or nucleic acids encoding prominin-1 or a regulatory region (e.g. a promoter region) of prominin-1, RNA aptamers against prominin-1, a ribozyme against nucleic acids encoding prominin-1, anti-sense nucleic acids hybridising with nucleic acids encoding prominin-1 and small interference RNA's (siRNA) against prominin-1.

The wording 'a molecule which comprises a region specifically binding to prominin-1 or nucleic acids encoding prominin-1' relates (1) on the one hand to molecules binding to nucleic acids encoding prominin-1 or to regulatory genetic regions of prominin-1, said molecules inhibit the gene expression of prominin-1 (thus the inhibition of prominin-1 transcription and/or translation of a gene transcript (mRNA) of prominin-1 and (2) on the other hand to molecules that inhibit the activity of the prominin-1 protein. The inhibition of gene expression can be measured conveniently by methods known in the art such as for example RT-PCR analysis of the prominin-1 transcript or for example western blot analysis of the prominin-1 protein, said inhibition is preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even higher. Measurement of molecules that bind to the

prominin-1 protein and inhibit the activity of prominin-1 can for example be carried out by various methods for determining pathological angiogenesis as described in the examples of the present invention. Said inhibition of prominin-1 activity is preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even higher. Thus in another

5 embodiment the invention provides the use of a molecule that inhibits the expression and/or activity of prominin-1 for the manufacture of a medicament for treatment of pathological angiogenesis. In the latter embodiment activity relates to the gene product (the protein) and expression relates to the gene: mRNA formation and/or translation of the mRNA of prominin-1.

10 The term 'antibody' or 'antibodies' relates to an antibody characterized as being specifically directed against prominin-1 or any functional derivative thereof, with said antibodies being preferably monoclonal antibodies; or an antigen-binding fragment thereof, of the F(ab')<sub>2</sub>, F(ab) or single chain Fv type, or any type of recombinant antibody derived thereof. These antibodies of the invention, including specific polyclonal antisera

15 prepared against prominin-1 or any functional derivative thereof, have no cross-reactivity to others proteins. The monoclonal antibodies of the invention can for instance be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly of a mouse or rat immunized against prominin-1 or any functional derivative thereof, and of cells of a myeloma cell line, and to be selected

20 by the ability of the hybridoma to produce the monoclonal antibodies recognizing prominin-1 or any functional derivative thereof which have been initially used for the immunization of the animals. The monoclonal antibodies according to this embodiment of the invention may be humanized versions of the mouse monoclonal antibodies made by means of recombinant DNA technology, departing from the mouse and/or human

25 genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains. Alternatively the monoclonal antibodies according to this embodiment of the invention may be human monoclonal antibodies. Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice as described in

30 PCT/EP 99/03605 or by using transgenic non-human animals capable of producing human antibodies as described in US patent 5,545,806. Also fragments derived from these monoclonal antibodies such as Fab, F(ab')<sub>2</sub> and ssFv ("single chain variable fragment"), providing they have retained the original binding properties, form part of the present invention. Such fragments are commonly generated by, for instance, enzymatic

35 digestion of the antibodies with papain, pepsin, or other proteases. It is well known to

the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses. The antibodies involved in the invention can be labeled by an appropriate label of the enzymatic, fluorescent, or radioactive type.

In a specific embodiment the antibodies against prominin-1 can be derived from animals of the camelid family. In said family immunoglobulins devoid of light polypeptide chains are found. Heavy chain variable domain sequences derived from camelids are designated as VHH's. "Camelids" comprise old world camelids (*Camelus bactrianus* and *Camelus dromaderius*) and new world camelids (for example *Lama paccos*, *Lama glama* and *Lama vicugna*). EP0656946 describes the isolation and uses of camelid immunoglobulins and is incorporated herein by reference.

Small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries.

Also within the scope of the invention are oligoribonucleotide sequences, that include anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of prominin-1 mRNA. Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. In regard to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g., between -10 and +10 regions of the prominin-1 nucleotide sequence, are preferred. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of prominin-1 RNA sequences.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

Both anti-sense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in

the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize anti-sense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

In a particular embodiment short interference RNA molecules (siRNA) can be used for the manufacture of a medicament for treatment of pathological angiogenesis. Said interference RNA molecules can be generated based on the genetic sequence of prominin-1 (SEQ ID NO: 1). RNA interference (RNAi) is based on the degradation of particular target sequences by the design of short interference RNA oligo's (siRNA) which recognize the target sequence (here SEQ ID NO: 1) and subsequently trigger their degradation by a poorly understood pathway. In general siRNA duplexes are shorter than 30 nucleotides, because longer stretches of dsRNA activate the PKR pathway in mammalian cells which results in a global a-specific shut-down of protein synthesis. The preparation and gene therapy vectors for the intracellular expression of siRNAs duplexes is disclosed in WO0244321 which is herein incorporated by reference.

In another particular embodiment RNA aptamers can be used for the manufacture of a medicament for treatment of pathological angiogenesis. Said RNA aptamers can be generated against prominin-1 (SEQ ID NO: 2). Recently, RNA aptamers have been used as therapeutic reagents for their ability to disrupt protein function. Selection of aptamers *in vitro* allows rapid isolation of extremely rare RNAs that have high specificity and affinity for specific proteins. Exemplary RNA aptamers are described in U.S. Pat. No. 5,270,163 to Gold et al., Ellington and Szostak, "In vitro Selection of RNA Molecules That Bind Specific Ligands," *Nature* 346:818-822 (1990), and Tuerk and Gold, "Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase," *Science* 249:505-510 (1990). Unlike antisense compounds, whose targets are one dimensional lattices, RNA aptamers can bind to the three dimensional surfaces of a protein. Moreover, RNA aptamers can frequently discriminate finely among discrete functional sites of a protein (Gold et al., "Diversity of Oligonucleotide Functions," *Annu. Rev. Biochem.* 64:763-797 (1995)). As research and therapeutic reagents, aptamers not only have the combined advantages of antibodies and small molecular mass drugs, but *in vivo* production of RNA aptamers also can be



controlled genetically. Such RNA expressing genes are usually smaller than protein-coding genes and can be inserted into gene therapy vectors.

The term 'pathological angiogenesis' refers to the excessive formation and growth of blood vessels during the maintenance and the progression of several disease states.

- 5 Examples where pathological angiogenesis can occur are blood vessels (atherosclerosis, hemangioma, hemangioendothelioma), bone and joints (rheumatoid arthritis, synovitis, bone and cartilage destruction, osteomyelitis, pannus growth, osteophyte formation, neoplasms and metastasis), skin (warts, pyogenic granulomas, hair growth, Kaposi's sarcoma, scar keloids, allergic oedema, neoplasms), liver, kidney,
- 10 lung, ear and other epithelia (inflammatory and infectious processes (including hepatitis, glomerulonephritis, pneumonia), asthma, nasal polyps, otitis, transplantation, liver regeneration, neoplasms and metastasis), uterus, ovary and placenta (dysfunctional uterine bleeding (due to intrauterine contraceptive devices), follicular cyst formation, ovarian hyperstimulation syndrome, endometriosis, neoplasms), brain, nerves and eye
- 15 (retinopathy of prematurity, diabetic retinopathy, choroidal and other intraocular disorders, leukomalacia, neoplasms and metastasis), heart and skeletal muscle due to work overload, adipose tissue (obesity), endocrine organs (thyroiditis, thyroid enlargement, pancreas transplantation), hematopoiesis (AIDS (Kaposi), hematologic malignancies (leukemias, etc.), tumour induced new blood vessels.
- 20 The term 'medicament to treat' relates to a composition comprising molecules as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat diseases as indicated above. Suitable carriers or excipients known to the skilled man are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance
- 25 isotonicity and chemical stability, buffers and preservatives. Other suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers. The 'medicament' may be administered by any suitable method within the knowledge of the
- 30 skilled man. The preferred route of administration is parenterally. In parental administration, the medicament of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above. However, the dosage and mode of administration will depend on the individual. Generally, the medicament is
- 35 administered so that the protein, peptide, antibody, small molecule, ribozyme, RNA

aptamer, anti-sense nucleic acid or siRNA of the present invention is given at a dose between 1  $\mu$ g/kg and 10 mg/kg, more preferably between 10  $\mu$ g/kg and 5 mg/kg, most preferably between 0.1 and 2 mg/kg. Preferably, it is given as a bolus dose. Continuous infusion may also be used and includes continuous subcutaneous delivery via an osmotic minipump. If so, the medicament may be infused at a dose between 5 and 20  $\mu$ g/kg/minute, more preferably between 7 and 15  $\mu$ g/kg/minute.

In another embodiment antibodies or functional fragments thereof can be used for the manufacture of a medicament for the treatment of the above mentioned disorders. As a non-limiting example there are the antibodies described in US 5,843,633. In a specific embodiment said antibodies are humanized (Rader et al., 2000, J. Biol. Chem. 275, 13668) and more specifically human antibodies are used to manufacture a medicament to treat pathological angiogenesis. In yet another specific embodiment antibodies derived from camelids are used to manufacture a medicament to treat pathological angiogenesis.

Another aspect of administration for treatment is the use of gene therapy to deliver the above mentioned anti-sense gene or functional parts of the prominin-1 gene or a ribozyme directed against the prominin-1 mRNA or a functional part thereof or RNA aptamers or siRNAs. Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells. This is extensively reviewed in Lever and Goodfellow 1995; Br. Med Bull., 51, 1-242; Culver 1995; Ledley, F.D. 1995. Hum. Gene Ther. 6, 1129. To achieve gene therapy there must be a method of delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes. There are two general approaches to achieve gene delivery; these are non-viral delivery and virus-mediated gene delivery.

The invention also provides methods for identifying compounds or molecules which bind on prominin-1 and prevent or suppress pathological angiogenesis. With "suppression" it is understood that said suppression can occur for at least 20%, 30%, 30%, 50%, 60%, 70%, 80%, 90% or even 100%.

Thus in another embodiment the invention provides a method to identify molecules that comprise a region that specifically binds to prominin-1 comprising: (1) exposing prominin-1 or nucleic acids encoding prominin-1 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined, (2) determining binding or hybridising of said molecule(s) to prominin-1 or nucleic acids

encoding prominin-1, and (3) monitoring said pathological angiogenesis when administering said molecules as a medicament.

The latter method is also referred to as 'drug screening assay' or 'bioassay' and typically include the step of screening a candidate/test compound or agent for the ability to interact with prominin-1. Candidate compounds or agents, which have this ability, can be used as drugs to combat or prevent pathological conditions of angiogenesis. Candidate/test compounds are described herein before and are for example RNA aptamers, others are small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries as described above. Typically, the assays are cell-free assays which include the steps of combining prominin-1 and a candidate/test compound (molecule), e.g., under conditions which allow for interaction of (e.g. binding of) the candidate/test compound with prominin-1 to form a complex, and detecting the formation of a complex, in which the ability of the candidate compound to interact with prominin-1 is indicated by the presence of the candidate compound in the complex. Formation of complexes between prominin-1 and the candidate compound can be quantitated, for example, using standard immunoassays. The prominin-1 employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located extracellularly or even intracellularly.

To perform the above described drug screening assays, it is feasible to immobilize prominin-1 or its (their) target molecule(s) to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Interaction (e.g., binding of) of prominin-1 to a target molecule, can be accomplished in any vessel suitable for containing the reactants.

Examples of such vessels include microtitre plates, test tubes, and microcentrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, prominin-1-His tagged can be adsorbed onto Ni-NTA microtitre plates, or prominin-1-ProtA fusions adsorbed to IgG, which are then combined with the cell lysates (e.g., <sup>35</sup>S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the plates are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of prominin-1-binding protein found in the bead fraction quantitated

from the gel using standard electrophoretic techniques. Other techniques for immobilizing protein on matrices can also be used in the drug screening assays of the invention. For example, prominin-1 can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated prominin-1 can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Another technique for drug screening which provides for high throughput screening of compounds having suitable binding affinity to prominin-1 is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO 84/03564, published on 13/09/84. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The protein test compounds are reacted with fragments of prominin-1 and washed. Bound prominin-1 is then detected by methods well known in the art. Purified prominin-1 can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support. This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding prominin-1 specifically compete with a test compound for binding prominin-1. In this manner, the antibodies can be used to detect the presence of any protein, which shares one or more antigenic determinants with prominin-1.

### Examples

#### 1. Generation of a prominin-1 knock-out mice

To study the *in vivo* role of PROM-1, PROM-1 (prominin-1) deficient mice were generated. Targeted inactivation of the PROM-1 gene was achieved by deletion of exon 2 (containing the start codon). Briefly, a genomic BAC (bacterial artificial chromosome) containing the murine PROM-1<sup>1</sup> was obtained from Research Genetics Inc (Huntsville, AL) after screening by PCR and hybridization. Mapping of the murine PROM-1 homologue gene revealed that the first exon, which is 79 bp long, is separated from the second exon by an approximately 8 kb intron. It is the second exon (376 bp long) that contains the startcodon ATG. A BamHI fragment of 11.5 kb containing exon 2 was subcloned into the pUC18 plasmid. A targeting vector for inactivation of the PROM-1 gene, pPNT.PROM-1<sup>null</sup>, was constructed consisting of, from 5' to 3': 1.2 kb of 5' homology comprising the end of intron 1; a *loxP*-flanked *neomycin* gene; 5.5 kb from

intron 2 as 3'-homology; and a *thymidine kinase* selection cassette outside of the regions of homology for counterselection against random integration events. The integrity of the construct was verified by restriction digestion and sequencing. The linearized targeting vector pPNT.PROM-1<sup>null</sup> was electroporated in R1 ES cells and targeted clones were identified by appropriate Southern blot analysis and used for morula aggregation to generate PROM-1 deficient chimeric and germline mice. PROM-1 deficient mice were born at the expected Mendelian frequency (~25% of 450 offspring from PROM-1 heterozygous breeding pairs). They appeared healthy and were fertile, irrespective of their genetic background (backgrounds tested: 50% Swiss/50% 129, 100% 129, 50% C57Bl6/50% 129). We anticipated that PROM-1 might play a crucial role in hematopoiesis implying that the PROM-1<sup>-/-</sup> embryo would die *in utero* either after the appearance of the primitive hematopoiesis (7.5 days post coitum, site: yolk sac) or at the emergence of the definitive hematopoiesis (12.5 days post coitum, site: fetal liver). Surprisingly, however, embryonic development in PROM-1<sup>-/-</sup> mice was normal. PROM-1<sup>-/-</sup> embryos were not rescued by maternal PROM-1, as PROM-1<sup>-/-</sup> embryos, sired by PROM-1<sup>+/-</sup> as well as by PROM-1<sup>-/-</sup> breeding pairs, developed normally. Also postnatal physiological vascular development seemed normal since no vascular defects could be observed in the heart (capillary density is  $5810 \pm 154$  in PROM-1<sup>+/-</sup> pups versus  $5394 \pm 179$  in PROM-1<sup>-/-</sup> pups,  $n=3$ ;  $p=NS$ ), kidneys, lungs and skeletal muscle during postnatal growth in PROM-1<sup>-/-</sup> mice.

## 2. Impaired pathological angiogenesis and/or vasculogenesis in prominin-1 knock-out mice

In order to study the role of PROM-1 in pathological conditions of angiogenesis PROM-1<sup>-/-</sup> mice and their wild-type littermates are subjected to various murine models of pathological blood vessel formation.

### 2.1 Ischemic retinopathy

PROM-1<sup>-/-</sup> mice and their wild-type littermates were subjected to a mouse model of ischemic retinopathy. In this hyperoxia-induced retinopathy model, neonatal mice (with an immature retinal vasculature) are exposed to hyperoxia, resulting in obliteration of the developing blood vessels supplying oxygen to the retina. When the mice are then returned to normoxia, the retina, distal to the occluded vessels, becomes ischemic,

inducing VEGF production and ultimately resulting in reproducible and quantifiable proliferative retinal neovascularization (33, 34). This model, which mimicks to a certain extent the vascular response during retinopathy of prematurity or diabetic retinopathy, may be useful to test the efficacy of (anti)-angiogenic molecules (Pierce EA et al (1995) Proc. Natl. Acad. Sci. 92(3)905-9). Mouse pups of 7 days (P7) together with their mothers, are subjected to hyperoxia (75% oxygen) in specially designed oxygen chambers for 5 days, without opening the cages. On P12, the animals are returned to room air until P17, when the retinas are assessed for maximal neovascular response. Anaesthetized mice are perfused through the left ventricle with 1 ml of phosphate buffered saline containing 50 mg of  $2 \times 10^6$  molecular weight fluorescein-dextran. The eyes are removed and fixed in 4% paraformaldehyde for 3 (right eye) or 24 (left eye) hrs. Of the right eyes, lenses are removed and peripheral retinas cut to allow flat mounting with glycerol-gelatin. The flat mounted retinas are analyzed by fluorescence microscopy. The left eyes are embedded in paraffin and serial 6  $\mu$ m sections are cut sagittally throughout the cornea, parallel to the optic nerve, and stained with hematoxylin-eosin. The proliferative neovascular response is quantified by counting the number of new vessels (= tufts) and the number of endothelial cells extending from the internal limiting membrane of the retina into the vitreum on the stained sagittal cross-sections. The angiographic technique using fluorescein-dextran perfusion is used in conjunction with this counting method for rapid screening of retinas or as an alternative grading system for quantitative evaluation. Loss of prominin-1 significantly protected mice against intra-vitreous neovascularization, as evaluated by counting the number of neovascular tufts and endothelial cells (EC) in the vitreous cavity ( $n=15$ ;  $p<0.001$ )

	N° of tufts in vitreous cavity (per 10 retinal sections)	N° of EC in vitreous cavity (per 10 retinal sections)
PROM-1 <sup>-/-</sup> <sup>+/+</sup> pups (n = 15)	157.1 $\pm$ 13.6	286.0 $\pm$ 45.1
PROM-1 <sup>-/-</sup> pups (n = 15)	72.5 $\pm$ 14.6	106.2 $\pm$ 22.6

## 2.2 Corneal micropocket assay

Hydron pellets containing an angiogenic substance (like bFGF or VEGF) are implanted into the corneal stroma adjacent to the temporal limbus. This induces neovascularization of the avascular corneal stroma from day 3 to day 8 after  
5 implantation, without substantial corneal edema or inflammation. Like the retinal hypoxia model, it gives a predictable, persistent and aggressive neovascular response, which is dependent on direct stimulation of blood vessels rather than on indirect stimulation by the induction of inflammation<sup>35</sup>. The mouse corneal micropocket assay was performed as previously described<sup>36</sup>. Hydron-coated sucralfate pellets containing 300 ng of  
10 VEGF<sub>165</sub> were positioned 1 mm from the corneal limbus. Mice deficient for PROM-1 showed a reduced angiogenic response. The length of the newly formed vessels ( $0.93 \pm 0.12$  mm in PROM-1<sup>+/+</sup> mice versus  $0.70 \pm 0.03$  mm in PROM-1<sup>-/-</sup> mice, n=6; p<0.005) as well as the circumferential neovascularity ( $6.23 \pm 0.55$  mm in PROM-1<sup>+/+</sup> mice versus  $3.60 \pm 0.32$  mm in PROM-1<sup>-/-</sup> mice, n=6; p<0.005) and the integrated optical density of  
15 the vessel area ( $497 \pm 100$  in PROM-1<sup>+/+</sup> mice versus  $196 \pm 27$  in PROM-1<sup>-/-</sup> mice, n=6; p<0.05) were significantly lower in the PROM-1 mice. Moreover, WT bone marrow transplantation into PROM-1 deficient mice rescued the impaired angiogenic response. The length of the newly formed vessels ( $0.57 \pm 0.03$  mm in PROM-1<sup>+/+</sup> mice versus  $0.57 \pm 0.03$  mm in PROM-1<sup>-/-</sup> mice, n=6; p<0.005) as well as the circumferential  
20 neovascularity ( $3.52 \pm 0.26$  mm in PROM-1<sup>+/+</sup> mice versus  $3.29 \pm 0.22$  mm in PROM-1<sup>-/-</sup> mice, n=6; p=NS) were identical in both PROM-1 deficient and WT mice after WT bone marrow transplantation.

## 2.3 Model of skin wound healing

25 Vascular remodeling was studied in a model of skin wound healing as described before<sup>37,38</sup>. For skin wounding, a standardised 15 mm full-thickness skin incision was made on the back of the mice, taking care not to damage the underlying muscle. Wound healing was quantified by daily measuring the width and the length of the wound. New blood vessel formation was analysed on skin sections harvested four days after wounding.  
30 Wound healing was significantly impaired in the PROM-1 deficient mice. Both genotypes contained comparable densities of vessels in unwounded skin. However, the number of capillaries infiltrating the wound ( $185.8 \pm 11.1$  vessels/mm<sup>2</sup> in PROM-1<sup>+/+</sup> mice versus  $135.0 \pm 12.7$  in PROM-1<sup>-/-</sup> mice, n=5; p<0.05), as well as the number of

smooth muscle-coated vessels in the wounded area ( $58.2 \pm 10$  vessels/mm<sup>2</sup> in PROM-1<sup>+/+</sup> mice versus  $28.6 \pm 4.022$  in PROM-1<sup>-/-</sup> mice, n=5; p<0.05) were significantly reduced in PROM-1 deficient mice.

#### 5     2.4 Matrigel assay

In-growth of capillaries was studied in a matrigel assay performed as described<sup>39</sup>. The angiogenic response in the matrigel of PROM-1<sup>-/-</sup> mice seemed somewhat lower as measured by the hemoglobin content per matrigel implant ( $137.0 \pm 20.4$  µg/ml in PROM-1<sup>+/+</sup> mice *versus*  $112.1 \pm 17.6$  µg/ml in PROM-1<sup>-/-</sup> mice; n=15; p= NS).

- 10     Histological sections of matrigel were then analysed for infiltration of leukocytes and for blood vessel formation after staining for inflammatory cells (CD45) and endothelial cells (CD31), respectively. The number of infiltrating leukocytes did not seem to differ but a reduced blood vessel formation (CD31 positive endothelial cells) was noticed in the matrigel implanted in PROM-1 deficient animals (% of CD31 positive area in matrigel:
- 15      $0.55 \pm 0.08\%$  in PROM-1<sup>+/+</sup> mice *versus*  $0.26 \pm 0.06\%$  in PROM-1<sup>-/-</sup> mice; n=5; p<0.05).

#### 2.5 Myocardial infarction model

Myocardial infarction was performed by ligation of the LAD as described<sup>40</sup>. After 4 to 7 days, infarcted hearts were used for histological analysis or for immunostaining of thrombomodulin (endothelial cells) or smooth muscle alpha-actin (smooth muscle cells)

20     <sup>38</sup>. Morphometric analysis and counting of immunoreactive cells was performed using an image analysis system with KS300 software (Zeiss, Brussels, Belgium). No differences were observed in the number of capillaries at 4 ( $490.9 \pm 65.4$  vessels/mm<sup>2</sup> in PROM-1<sup>+/+</sup> mice *versus*  $493.3 \pm 87.7$  vessels/mm<sup>2</sup> in PROM-1<sup>-/-</sup> mice; n=3; p= NS) or

25     7 days ( $510.6 \pm 28.3$  vessels/mm<sup>2</sup> in PROM-1<sup>+/+</sup> mice *versus*  $507.8 \pm 24.6$  vessels/mm<sup>2</sup> in PROM-1<sup>-/-</sup> mice; n=10; p= NS) after ligation or in the number of SMC covered vessels at 4 ( $20.3 \pm 3.2$  vessels/mm<sup>2</sup> in PROM-1<sup>+/+</sup> mice *versus*  $23.3 \pm 6.73$  vessels/mm<sup>2</sup> in PROM-1<sup>-/-</sup> mice; n=3; p= NS) or at 7 days ( $87.6 \pm 14.3$  vessels/mm<sup>2</sup> in PROM-1<sup>+/+</sup> mice *versus*  $76.4 \pm 12.2$  vessels/mm<sup>2</sup> in PROM-1<sup>-/-</sup> mice; n=10; p= NS) in

30     the infarcted area of hearts of PROM-1 deficient mice and wild-type littermates. However, a clear significant difference was observed in the number of infiltrating macrophages at 7 days after ligation (% of Mac3 positive area:  $3.75 \pm 0.77\%$  in PROM-1<sup>+/+</sup> mice *versus*  $1.62 \pm 0.42\%$  in PROM-1<sup>-/-</sup> mice; n=10; p< 0.05).



### 2.6 Hind limb ischemia model

Hind limb ischemia is induced as described <sup>41</sup>. Unilateral right or bilateral ligations of the femoral artery and vein (proximal to the popliteal artery) and the cutaneous vessels branching from the caudal femoral artery side branch is performed and two superficial preexisting collateral arterioles, connecting the femoral and saphenous artery, will be used for analysis. Genetic consequences on post-ischemic revascularization is determined 14 days after ligation, using vascular morphological (histological evaluation of capillary density and SMC-coated vessel density, histological evaluation of myocyte necrosis and regeneration), perfusional (fluorescent microspheres, laser Doppler imaging), and functional (graded treadmill exercise or swim endurance exercise) analyses.

### 2.7 Tumor models

The role of PROM-1 is also tested in tumor models. The following mouse models are operational and are used to analyze tumor angiogenesis in vivo: 1) subcutaneous injection of ras-transformed fibroblasts in athymic nude (nu/nu) mice, 2) subcutaneous injection of Lewis lung carcinoma cells in syngenic C57Bl6 hosts, and 3) subcutaneous inoculation of rat C6 glioma cells of athymic nude (nu/nu) mice. Five to twenty million of tumor cells are inoculated in the mice and tumor growth is followed up to 30 days. Tumors are measured with calipers and tumor volumes calculated using the formula  $[\pi/6 \times (w1 \times w2 \times w2)]$ , where "w1" and "w2" represent the largest and smallest tumor diameter, respectively. Tumor vessel density and size are determined on tissue sections using immunohistochemistry for visualization of endothelial cells (CD-31), in combination with quantitative morphometry of vascular densities and patterning. If necessary, intratumor flow is determined using colored microspheres to quantitate flow across the entire tumor. When WT RAS transformed fibroblasts were injected in PROM-1 deficient and WT nude mice, no difference in tumor weight was seen (tumor weight after 14 days:  $0.9 \pm 0.1$  g in PROM-1<sup>+/+</sup> hosts versus  $1.1 \pm 0.3$  g in PROM-1<sup>-/-</sup> hosts; n=7; p< 0.05). Blood vessel analysis is being performed. Remarkably, the number of infiltrating leukocytes was significantly reduced in the tumors grown in the PROM-1 deficient mice.

### 2.8 LPS induced venous thrombosis in footpad

To study whether PROM-1 is important in inflammatory processes, a chronic

inflammation footpad assay was used. Endotoxin (20 $\mu$ l, *E. coli* lipopolysaccharide, 5 and 50  $\mu$ g/ml) was injected into the right footpad of both PROM-1 deficient and WT mice as described (Carmeliet, P. et al (1993) *J. Clin. Invest* 6: 2756-60). Saline is injected into the left footpad as a control. After 5 days, mice were sacrificed and both right and left footpad were measured with callipers, excised and fixed in 1% paraformaldehyde for 24 hours. Subsequently, footpads were embedded in paraffin and sectioned. Veins are scored on haematoxylin and eosin stained sections for the presence of thrombi. Five days after injecting 50  $\mu$ g/ml of endotoxin, a decrease in footpad thickness was observed in the PROM-1 deficient compared to their WT controls.

10

These data clearly indicate a role of AC 133 in pathological vasculogenesis and/or angiogenesis and implicate the use of inhibitors of PROM-1 in therapeutic strategies to inhibit blood vessel formation in various pathological disorders.

References

1. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90(12):5013-21.
2. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. PROM-1, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90(12):5002-12.
3. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N and others. In vitro differentiation of endothelial cells from PROM-1-positive progenitor cells. Blood 2000;95(10):3106-12.
4. Boyer M, Townsend LE, Vogel LM, Falk J, Reitz-Vick D, Trevor KT, Villalba M, Bendick PJ, Glover JL. Isolation of endothelial cells and their progenitor cells from human peripheral blood. J Vasc Surg 2000;31(1 Pt 1):181-9.
5. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 2001;115(1):186-94.
6. Buhring HJ, Seiffert M, Bock TA, Scheduling S, Thiel A, Scheffold A, Kanz L, Brugger W. Expression of novel surface antigens on early hematopoietic cells. Ann N Y Acad Sci 1999;872:25-38; discussion 38-9.
7. Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D. Expression of PROM-1, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. Blood 1999;93(4):1435-7.
8. Kratz-Albers K, Zuhlsdorf M, Leo R, Berdel WL, Buchner T, Serve H. Expression of a PROM-1, a novel stem cell marker, on human leukemic blasts lacking CD34-antigen and on a human CD34+ leukemic line:MUTZ-2. Blood 1998;92(11):4485-7.
9. Buhring HJ, Seiffert M, Marxer A, Weiss B, Faul C, Kanz L, Brugger W. PROM-1 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. Blood 1999;94(2):832-3.
10. Corbeil D, Roper K, Hannah MJ, Hellwig A, Huttner WB. Selective localization of the polytopic membrane protein prominin in microvilli of epithelial cells - a combination of apical sorting and retention in plasma membrane protrusions. J Cell Sci 1999;112(Pt 7):1023-33.

11. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA and others. Expression of VEGFR-2 and PROM-1 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. *Blood* 2000;95(3):952-8.
- 5 12. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. *J Clin Invest* 2000;105(1):17-9.
13. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. Direct isolation of human central nervous system stem cells. *Proc Natl Acad Sci U S A* 2000;97(26):14720-5.
- 10 14. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB. The human PROM-1 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. *J Biol Chem* 2000;275(8):5512-20.
- 15 15. Yu Y, Flint A, Dvorin EL, Bischoff J. PROM-1-2, a Novel Isoform of Human PROM-1 Stem Cell Antigen. *J Biol Chem* 2002;277(23):20711-6.
16. Maw MA, Corbeil D, Koch J, Hellwig A, Wilson-Wheeler JC, Bridges RJ, Kumaramanickavel G, John S, Nancarrow D, Roper K and others. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. *Hum Mol Genet* 2000;9(1):27-34.
- 20 17. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. *Traffic* 2001;2(2):82-91.
18. Corbeil D, Roper K, Weigmann A, Huttner WB. PROM-1 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(7):2625-6.
- 25 19. Miraglia S, Godfrey W, Buck D. A response to PROM-1 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(11):4390-1.
20. Risau W. Mechanisms of angiogenesis. *Nature* 1997;386(6626):671-4.
- 30 21. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275(5302):964-7.
22. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR and others. Evidence for circulating bone marrow-derived endothelial cells. *Blood* 1998;92(2):362-7.
- 35

23. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med* 1999;5(4):434-8.
- 5 24. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 1999;85(3):221-8.
- 10 25. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *Embo J* 1999;18(14):3964-72.
- 15 26. Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, Storb RF, Sauvage LR, Hammond WP, Wu MH. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. *Blood* 2000;95(2):581-5.
- 20 27. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci U S A* 2000;97(7):3422-7.
- 25 28. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. *J Clin Invest* 2000;106(4):571-8.
- 30 29. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM and others. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. *Circulation* 2001;103(5):634-7.
- 30 30. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 2001;7(4):430-6.
31. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 2001;89(1):E1-7.

32. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)PROM-1(+) endothelial precursor cells. *Circ Res* 2001;88(2):167-74.
- 5 33. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):101-11.
34. Wesolowski E, Smith LE. Effect of light on oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):112-9.
- 10 35. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. *Invest Ophthalmol Vis Sci* 1996;37(8):1625-32.
- 15 36. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF- induced postnatal neovascularization. *Circ Res* 1998;83(3):233-40.
37. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. *J Biol Chem* 1995;270(21):12607-13.
- 20 38. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernelle V, De Mol M, Wu Y, Bono F, Devy L, Beck H and others. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat Med* 2001;7(5):575-83.
- 25 39. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. *Lab Invest* 1992;67(4):519-28.
- 30 40. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angelillo A and others. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. *Nat Med* 1999;5(10):1135-42.
41. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B and others. Revascularization of ischemic tissues by

PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. *Nat Med* 2002;8(8):831-40.

42. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. *Genes Dev* 1999;13(9):1055-66.

43. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nat Med* 2000;6(4):389-95.

44. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K and others. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. *Am J Pathol* 1999;154(2):385-94.

45. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. *Cell* 1999;98(6):769-78.

46. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. *Trends Immunol* 2001;22(6):317-21.

47. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG and others. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. *Embo J* 2001;20(6):1223-31.

48. Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic endothelium: in search of the holy grail? *Microsc Res Tech* 2001;55(2):61-9.

49. Witte MH, Bernas MJ, Martin CP, Witte CL. Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. *Microsc Res Tech* 2001;55(2):122-45.

50. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. *Cancer Res* 2001;61(5):1786-90.

51. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG and others. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. *Embo J* 2001;20(4):672-82.

52. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat Med* 2001;7(2):192-8.
53. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. *Nat Med* 2001;7(2):186-91.
54. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. *Cancer Cell* 2002;1(3):219-27.
55. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. *Genes Dev* 2002;16(7):773-83.
56. Schneider M, Othman-Hassan K, Christ B, Wilting J. Lymphangioblasts in the avian wing bud. *Dev Dyn* 1999;216(4-5):311-9.
57. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. *Proc Natl Acad Sci U S A* 2002;99(13):8868-73.
58. Folkman J. A mechanism for regulation of lymphangiogenesis independent of angiogenesis. Bethesda; 2002.
59. Baldwin M, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, Karkkainen MJ, Alitalo K, Stacker SA, M.G. A. The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man. *J. Biol. Chem.* 2001;276(22):19166-19171.
60. Boardman KC, Swartz MA. Lymphangiogenesis in a mouse tail model. 2001. p 671-672.
61. Ikomi F, Ohhashi T. Immunohistochemical expression of VEGF receptors on new vascularization of collecting lymphatics in mice. In: Editore M, editor; 2001; Sidney, Australia. p 387-390.
62. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. *Science* 1992;255(5052):1707-10.
63. Gage FH. Mammalian neural stem cells. *Science* 2000;287(5457):1433-8.
64. Yamamoto S, Yamamoto N, Kitamura T, Nakamura K, Nakafuku M. Proliferation of parenchymal neural progenitors in response to injury in the adult rat spinal cord. *Exp Neurol* 2001;172(1):115-27.



65. Cao Q, Benton RL, Whittemore SR. Stem cell repair of central nervous system injury. *J Neurosci Res* 2002;68(5):501-10.
66. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. *Nat Med* 2002;8(9):963-70.
- 5 67. Kempermann G, Kuhn HG, Gage FH. Genetic influence on neurogenesis in the dentate gyrus of adult mice. *Proc Natl Acad Sci U S A* 1997;94(19):10409-14.
68. Kuhn HG, Palmer TD, Fuchs E. Adult neurogenesis: a compensatory mechanism for neuronal damage. *Eur Arch Psychiatry Clin Neurosci* 2001;251(4):152-8.
- 10 69. Gritti A, Parati EA, Cova L, Frolichsthal P, Galli R, Wanke E, Faravelli L, Morassutti DJ, Roisen F, Nickel DD and others. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. *J Neurosci* 1996;16(3):1091-100.
70. Takagi Y, Mitsui A, Nishiyama A, Nozaki K, Sono H, Gon Y, Hashimoto N, Yodoi J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. *Proc Natl Acad Sci U S A* 1999;96(7):4131-6.
- 15 71. Tamaki S, Eckert K, He D, Sutton R, Doshe M, Jain G, Tushinski R, Reitsma M, Harris B, Tsukamoto A and others. Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. *J Neurosci Res* 2002;69(6):976-86.
- 20 72. Wu S, Suzuki Y, Kitada M, Kataoka K, Kitaura M, Chou H, Nishimura Y, Ide C. New method for transplantation of neurosphere cells into injured spinal cord through cerebrospinal fluid in rat. *Neurosci Lett* 2002;318(2):81-4.
73. Lang-Lazdunski L, Matsushita K, Hirt L, Waeber C, Vonsattel JP, Moskowitz MA, Dietrich WD. Spinal cord ischemia. Development of a model in the mouse. *Stroke* 2000;31(1):208-13.
- 25 74. Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, Solomon A, Gepstein R, Katz A, Belkin M and others. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. *Nat Med* 1998;4(7):814-21.

Claims

5 1. Use of a molecule that inhibits the expression and/or activity of prominin-1 for the manufacture of a medicament for treatment of pathological angiogenesis.

2. Use of a molecule according to claim 1 wherein said molecule is chosen from the list comprising an antibody or any fragment thereof, a small molecule, an RNA aptamer, a peptide, a ribozyme, anti-sense nucleic acids and siRNA.

10 3. A method to identify molecules that comprise a region that specifically binds to prominin-1 comprising:

- exposing prominin-1 or nucleic acids encoding prominin-1 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined,
- 15 - determining binding or hybridising of said molecule(s) to prominin-1 or nucleic acids encoding prominin-1, and
- monitoring said pathological angiogenesis when administering said molecules as a medicament.

## SEQUENCE LISTING

<110> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW

<120> A NOVEL TARGET TO INHIBIT ANGIOGENESIS

<130> VIB-034-PCT

<150> EP02075544.3

<151> 2002-02-08

<150> EP02077742.1

<151> 2002-07-09

<150> EP03100148.0

<151> 2003-01-24

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 3794

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (38)..(2635)

<223>

<400> 1  
ccaagttcta cctcatgttt ggaggatctt gctagct atg gcc ctc gta ctc ggc 55  
Met Ala Leu Val Leu Gly  
1 5

tcc ctg ttg ctg ctg ggg ctg tgc ggg aac tcc ttt tca gga ggg cag 103



1

## VIB-034-PCT.ST25.txt

Ser	Leu	His	Gln	Gln	Ser	Thr	Gln	Leu	Ser	Ser	Ser	Leu	Thr	Ser	Val	
280					285						290					
aaa Lys 295	act Thr	agc Ser	ctg Leu	cgg Arg	tca Ser 300	tct Ser	ctc Leu	aat Asn	gac Asp	cct Pro 305	ctg Leu	tgc Cys	ttg Leu	gtg Val	cat His 310	967
cca Pro	tca Ser	agt Ser	gaa Glu 315	acc Thr	tgc Cys	aac Asn	agc Ser	atc Ile	aga Arg 320	ttg Leu	tct Ser	cta Leu	agc Ser	cag Gln 325	ctg Leu	1015
aat Asn	agc Ser	aac Asn	cct Pro 330	gaa Glu	ctg Leu	agg Arg	cag Gln	ctt Leu 335	cca Pro	ccc Pro	gtg Val	gat Asp	gca Ala 340	gaa Glu	ctt Leu	1063
gac Asp	aac Asn	gtt Val 345	aat Asn	aac Asn	gtt Val	ctt Leu	agg Arg 350	aca Thr	gat Asp	ttg Leu	gat Asp	ggc Gly 355	ctg Leu	gtc Val	caa Gln	1111
cag Gln	ggc Gly 360	tat Tyr	caa Gln	tcc Ser	ctt Leu	aat Asn 365	gat Asp	ata Ile	cct Pro	gac Asp	aga Arg 370	gta Val	caa Gln	cgc Arg	caa Gln	1159
acc Thr 375	acg Thr	act Thr	gtc Val	gta Val	gca Ala 380	ggg Gly	atc Ile	aaa Lys	agg Arg	gtc Val 385	ttg Leu	aat Asn	tcc Ser	att Ile	ggg Gly 390	1207
tca Ser	gat Asp	atc Ile	gac Asp	aat Asn 395	gta Val	act Thr	cag Gln	cgt Arg	ctt Leu 400	cct Pro	att Ile	cag Gln	gat Asp	ata Ile 405	ctc Leu	1255
tca Ser	gca Ala	ttc Phe	tct Ser 410	gtt Val	tat Tyr	gtt Val	aat Asn	aac Asn 415	act Thr	gaa Glu	agt Ser	tac Tyr	atc Ile 420	cac His	aga Arg	1303
aat Asn	tta Leu	cct Pro 425	aca Thr	ttg Leu	gaa Glu	gag Glu	tat Tyr 430	gat Asp	tca Ser	tac Tyr	tgg Trp 435	tgg Trp	ctg Leu	ggg Gly	ggc Gly	1351
ctg Leu	gtc Val 440	atc Ile	tgc Cys	tct Ser	ctg Leu	ctg Leu 445	acc Thr	ctc Leu	atc Ile	gtg Val 450	att Ile	ttt Phe	tac Tyr	tac Tyr	ctg Leu	1399
ggc Gly 455	tta Leu	ctg Leu	tgt Cys	ggc Gly	gtg Val 460	tgc Cys	ggc Gly	tat Tyr	gac Asp	agg Arg 465	cat His	gcc Ala	acc Thr	ccg Pro	acc Thr 470	1447
acc Thr	cga Arg	ggc Gly	tgt Cys	gtc Val 475	tcc Ser	aac Asn	acc Thr	gga Gly	ggc Gly 480	gtc Val	ttc Phe	ctc Leu	atg Met	gtt Val 485	gga Gly	1495
gtt Val	gga Gly	tta Leu	agt Ser 490	ttc Phe	ctc Leu	ttt Phe	tgc Cys	tgg Trp 495	ata Ile	ttg Leu	atg Met	atc Ile	att Ile 500	gtg Val	gtt Val	1543
ctt Leu	acc Thr	ttt Phe 505	gtc Val	ttt Phe	ggg Gly	gca Ala	aat Asn 510	gtg Val	gaa Glu	aaa Lys	ctg Leu	atc Ile 515	tgt Cys	gaa Glu	cct Pro	1591
tac Tyr	acg Thr 520	agc Ser	aag Lys	gaa Glu	tta Leu	ttc Phe 525	cgg Arg	gtt Val	ttg Leu	gat Asp	aca Thr 530	ccc Pro	tac Tyr	tta Leu	cta Leu	1639
aat Asn 535	gaa Glu	gac Asp	tgg Trp	gaa Glu	tac Tyr 540	tat Tyr	ctc Leu	tct Ser	ggg Gly 545	aag Lys	cta Leu	ttt Phe	aat Asn	aaa Lys	tca Ser 550	1687
aaa	atg	aag	ctc	act	ttt	gaa	caa	gtt	tac	agt	gac	tgc	aaa	aaa	aat	1735

## VIB-034-PCT.ST25.txt

Lys	Met	Lys	Leu	Thr 555	Phe	Glu	Gln	Val	Tyr 560	Ser	Asp	Cys	Lys	Lys 565	Asn	
aga	ggc	act	tac	ggc	act	ctt	cac	ctg	cag	aac	agc	ttc	aat	atc	agt	1783
Arg	Gly	Thr	Tyr 570	Gly	Thr	Leu	His	Leu 575	Gln	Asn	Ser	Phe	Asn 580	Ile	Ser	
gaa	cat	ctc	aac	att	aat	gag	cat	act	gga	agc	ata	agc	agt	gaa	ttg	1831
Glu	His	Leu 585	Asn	Ile	Asn	Glu	His 590	Thr	Gly	Ser	Ile	Ser 595	Ser	Glu	Leu	
gaa	agt	ctg	aag	gta	aat	ctt	aat	atc	ttt	ctg	ttg	ggt	gca	gca	gga	1879
Glu	Ser 600	Leu	Lys	Val	Asn	Leu 605	Asn	Ile	Phe	Leu	Leu 610	Gly	Ala	Ala	Gly	
aga	aaa	aac	ctt	cag	gat	ttt	gct	gct	tgt	gga	ata	gac	aga	atg	aat	1927
Arg 615	Lys	Asn	Leu	Gln	Asp 620	Phe	Ala	Ala	Cys	Gly 625	Ile	Asp	Arg	Met	Asn 630	
tat	gac	agc	tac	ttg	gct	cag	act	ggt	aaa	tcc	ccc	gca	gga	gtg	aat	1975
Tyr	Asp	Ser	Tyr	Leu 635	Ala	Gln	Thr	Gly	Lys 640	Ser	Pro	Ala	Gly	Val 645	Asn	
ctt	tta	tca	ttt	gca	tat	gat	cta	gaa	gca	aaa	gca	aac	agt	ttg	ccc	2023
Leu	Leu	Ser	Phe 650	Ala	Tyr	Asp	Leu	Glu 655	Ala	Lys	Ala	Asn	Ser 660	Leu	Pro	
cca	gga	aat	ttg	agg	aac	tcc	ctg	aaa	aga	gat	gca	caa	act	att	aaa	2071
Pro	Gly	Asn 665	Leu	Arg	Asn	Ser	Leu 670	Lys	Arg	Asp	Ala	Gln 675	Thr	Ile	Lys	
aca	att	cac	cag	caa	cga	gtc	ctt	cct	ata	gaa	caa	tca	ctg	agc	act	2119
Thr	Ile 680	His	Gln	Gln	Arg	Val 685	Leu	Pro	Ile	Glu	Gln 690	Ser	Leu	Ser	Thr	
cta	tac	caa	agc	gtc	aag	ata	ctt	caa	cgc	aca	ggg	aat	gga	ttg	ttg	2167
Leu 695	Tyr	Gln	Ser	Val	Lys 700	Ile	Leu	Gln	Arg	Thr 705	Gly	Asn	Gly	Leu	Leu 710	
gag	aga	gta	act	agg	att	cta	gct	tct	ctg	gat	ttt	gct	cag	aac	ttc	2215
Glu	Arg	Val	Thr 715	Arg	Ile	Leu	Ala	Ser	Leu 720	Asp	Phe	Ala	Gln	Asn 725	Phe	
atc	aca	aac	aat	act	tcc	tct	gtt	att	att	gag	gaa	act	aag	aag	tat	2263
Ile	Thr	Asn 730	Asn	Thr	Ser	Ser	Val	Ile 735	Ile	Glu	Glu	Thr	Lys 740	Lys	Tyr	
ggg	aga	aca	ata	ata	gga	tat	ttt	gaa	cat	tat	ctg	cag	tgg	atc	gag	2311
Gly	Arg	Thr 745	Ile	Ile	Gly	Tyr	Phe 750	Glu	His	Tyr	Leu	Gln 755	Trp	Ile	Glu	
ttc	tct	atc	agt	gag	aaa	gtg	gca	tcg	tgc	aaa	cct	gtg	gcc	acc	gct	2359
Phe 760	Ser	Ile	Ser	Glu	Lys	Val 765	Ala	Ser	Cys	Lys	Pro 770	Val	Ala	Thr	Ala	
cta	gat	act	gct	gtt	gat	gtc	ttt	ctg	tgt	agc	tac	att	atc	gac	ccc	2407
Leu 775	Asp	Thr	Ala	Val	Asp 780	Val	Phe	Leu	Cys	Ser 785	Tyr	Ile	Ile	Asp	Pro 790	
ttg	aat	ttg	ttt	tgg	ttt	ggc	ata	gga	aaa	gct	act	gta	ttt	tta	ctt	2455
Leu	Asn	Leu	Phe 795	Trp	Phe	Gly	Ile	Gly 800	Lys	Ala	Thr	Val	Phe 805	Leu	Leu	
ccg	gct	cta	att	ttt	gcg	gta	aaa	ctg	gct	aag	tac	tat	cgt	cga	atg	2503
Pro	Ala	Leu 810	Ile	Phe	Ala	Val	Lys	Leu 815	Ala	Lys	Tyr	Tyr	Arg 820	Arg	Met	
gat	tcg	gag	gac	gtg	tac	gat	gat	gtt	gaa	act	ata	ccc	atg	aaa	aat	2551

## VIB-034-PCT.ST25.txt

Asp Ser Glu Asp Val Tyr Asp Asp Val Glu Thr Ile Pro Met Lys Asn  
 825 830 835  
 atg gaa aat ggt aat aat ggt tat cat aaa gat cat gta tat ggt att 2599  
 Met Glu Asn Gly Asn Asn Gly Tyr His Lys Asp His Val Tyr Gly Ile  
 840 845 850  
 cac aat cct gtt atg aca agc cca tca caa cat tga tagctgatgt 2645  
 His Asn Pro Val Met Thr Ser Pro Ser Gln His  
 855 860 865  
 tgaaactgct tgagcatcag gatactcaaa gtggaaagga tcacagattt ttggtagt 2705  
 ctgggtctac aaggactttc caaatccagg agcaacgcca gtggcaacgt agtgactcag 2765  
 gcgggaccca aggcaacggc accattgggtc tctgggtagt gctttaagaa.tgaacacaat 2825  
 cacgttatag tccatgggtcc atcactattc aaggatgact ccctcccttc ctgtctattt 2885  
 ttgtttttta ctttttttaca ctgagtttct atttagacac tacaacatat ggggtgtttg 2945  
 ttcccattgg atgcatttct atcaaaactc tatcaaatgt gatggctaga ttctaacata 3005  
 ttgccatgtg tggagtgtgc tgaacacaca ccagtttaca ggaaagatgc attttgtgta 3065  
 cagtaaacgg tgtatatacc ttttgttacc acagagtttt ttaaacaaat gagtattata 3125  
 ggactttctt ctaaatagagc taaataagtc accattgact tcttgggtgct gttgaaaata 3185  
 atccattttc actaaaagtg tgtgaaacct acagcatatt cttcacgcag agattttcat 3245  
 ctattatact ttatcaaaga ttggccatgt tccacttggg aatggcatgc aaaagccatc 3305  
 atagagaaac ctgcgtaact ccatctgaca aattcaaaag agagagagag atcttgagag 3365  
 agaaatgctg ttcgttcaaa agtggagttg ttttaacaga tgccaattac ggtgtacagt 3425  
 ttaacagagt tttctgttgc attaggataa acattaattg gagtgcagct aacatgagta 3485  
 tcatcagact agtatcaagt gttctaaaat gaaatatgag aagatcctgt cacaattctt 3545  
 agatctgggtg tccagcatgg atgaaacctt tgagtttggt ccctaaattt gcatgaaagc 3605  
 acaaggtaaa tattcatttg cttcaggagt ttcattgttg atctgtcatt atcaaaagtg 3665  
 atcagcaatg aagaactggt cggacaaaat ttaacgttga tgtaatggaa ttccagatgt 3725  
 aggcattccc cccagggtctt ttcattgtgca gattgcagtt ctgattcatt tgaataaaaa 3785  
 ggaacttgg 3794

&lt;210&gt; 2

&lt;211&gt; 865

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Ala Leu Val Leu Gly Ser Leu Leu Leu Leu Gly Leu Cys Gly Asn  
 1 5 10 15

VIB-034-PCT.ST25.txt

Ser Phe Ser Gly Gly Gln Pro Ser Ser Thr Asp Ala Pro Lys Ala Trp  
 20 25 30

Asn Tyr Glu Leu Pro Ala Thr Asn Tyr Glu Thr Gln Asp Ser His Lys  
 35 40 45

Ala Gly Pro Ile Gly Ile Leu Phe Glu Leu Val His Ile Phe Leu Tyr  
 50 55 60

Val Val Gln Pro Arg Asp Phe Pro Glu Asp Thr Leu Arg Lys Phe Leu  
 65 70 75 80

Gln Lys Ala Tyr Glu Ser Lys Ile Asp Tyr Asp Lys Pro Glu Thr Val  
 85 90 95

Ile Leu Gly Leu Lys Ile Val Tyr Tyr Glu Ala Gly Ile Ile Leu Cys  
 100 105 110

Cys Val Leu Gly Leu Leu Phe Ile Ile Leu Met Pro Leu Val Gly Tyr  
 115 120 125

Phe Phe Cys Met Cys Arg Cys Cys Asn Lys Cys Gly Gly Glu Met His  
 130 135 140

Gln Arg Gln Lys Glu Asn Gly Pro Phe Leu Arg Lys Cys Phe Ala Ile  
 145 150 155 160

Ser Leu Leu Val Ile Cys Ile Ile Ile Ser Ile Gly Ile Phe Tyr Gly  
 165 170 175

Phe Val Ala Asn His Gln Val Arg Thr Arg Ile Lys Arg Ser Arg Lys  
 180 185 190

Leu Ala Asp Ser Asn Phe Lys Asp Leu Arg Thr Leu Leu Asn Glu Thr  
 195 200 205

Pro Glu Gln Ile Lys Tyr Ile Leu Ala Gln Tyr Asn Thr Thr Lys Asp  
 210 215 220

Lys Ala Phe Thr Asp Leu Asn Ser Ile Asn Ser Val Leu Gly Gly Gly  
 225 230 235 240

Ile Leu Asp Arg Leu Arg Pro Asn Ile Ile Pro Val Leu Asp Glu Ile  
 245 250 255

Lys Ser Met Ala Thr Ala Ile Lys Glu Thr Lys Glu Ala Leu Glu Asn  
 260 265 270

Met Asn Ser Thr Leu Lys Ser Leu His Gln Gln Ser Thr Gln Leu Ser  
 275 280 285



## VIB-034-PCT.ST25.txt

Ser Ser Leu Thr Ser Val Lys Thr Ser Leu Arg Ser Ser Leu Asn Asp  
 290 295 300

Pro Leu Cys Leu Val His Pro Ser Ser Glu Thr Cys Asn Ser Ile Arg  
 305 310 315 320

Leu Ser Leu Ser Gln Leu Asn Ser Asn Pro Glu Leu Arg Gln Leu Pro  
 325 330 335

Pro Val Asp Ala Glu Leu Asp Asn Val Asn Asn Val Leu Arg Thr Asp  
 340 345 350

Leu Asp Gly Leu Val Gln Gln Gly Tyr Gln Ser Leu Asn Asp Ile Pro  
 355 360 365

Asp Arg Val Gln Arg Gln Thr Thr Thr Val Val Ala Gly Ile Lys Arg  
 370 375 380

Val Leu Asn Ser Ile Gly Ser Asp Ile Asp Asn Val Thr Gln Arg Leu  
 385 390 395 400

Pro Ile Gln Asp Ile Leu Ser Ala Phe Ser Val Tyr Val Asn Asn Thr  
 405 410 415

Glu Ser Tyr Ile His Arg Asn Leu Pro Thr Leu Glu Glu Tyr Asp Ser  
 420 425 430

Tyr Trp Trp Leu Gly Gly Leu Val Ile Cys Ser Leu Leu Thr Leu Ile  
 435 440 445

Val Ile Phe Tyr Tyr Leu Gly Leu Leu Cys Gly Val Cys Gly Tyr Asp  
 450 455 460

Arg His Ala Thr Pro Thr Thr Arg Gly Cys Val Ser Asn Thr Gly Gly  
 465 470 475 480

Val Phe Leu Met Val Gly Val Gly Leu Ser Phe Leu Phe Cys Trp Ile  
 485 490 495

Leu Met Ile Ile Val Val Leu Thr Phe Val Phe Gly Ala Asn Val Glu  
 500 505 510

Lys Leu Ile Cys Glu Pro Tyr Thr Ser Lys Glu Leu Phe Arg Val Leu  
 515 520 525

Asp Thr Pro Tyr Leu Leu Asn Glu Asp Trp Glu Tyr Tyr Leu Ser Gly  
 530 535 540

Lys Leu Phe Asn Lys Ser Lys Met Lys Leu Thr Phe Glu Gln Val Tyr  
 545 550 555 560

VIB-034-PCT.ST25.txt

Ser Asp Cys Lys Lys Asn Arg Gly Thr Tyr Gly Thr Leu His Leu Gln  
 565 570 575

Asn Ser Phe Asn Ile Ser Glu His Leu Asn Ile Asn Glu His Thr Gly  
 580 585 590

Ser Ile Ser Ser Glu Leu Glu Ser Leu Lys Val Asn Leu Asn Ile Phe  
 595 600 605

Leu Leu Gly Ala Ala Gly Arg Lys Asn Leu Gln Asp Phe Ala Ala Cys  
 610 615 620

Gly Ile Asp Arg Met Asn Tyr Asp Ser Tyr Leu Ala Gln Thr Gly Lys  
 625 630 635 640

Ser Pro Ala Gly Val Asn Leu Leu Ser Phe Ala Tyr Asp Leu Glu Ala  
 645 650 655

Lys Ala Asn Ser Leu Pro Pro Gly Asn Leu Arg Asn Ser Leu Lys Arg  
 660 665 670

Asp Ala Gln Thr Ile Lys Thr Ile His Gln Gln Arg Val Leu Pro Ile  
 675 680 685

Glu Gln Ser Leu Ser Thr Leu Tyr Gln Ser Val Lys Ile Leu Gln Arg  
 690 695 700

Thr Gly Asn Gly Leu Leu Glu Arg Val Thr Arg Ile Leu Ala Ser Leu  
 705 710 715 720

Asp Phe Ala Gln Asn Phe Ile Thr Asn Asn Thr Ser Ser Val Ile Ile  
 725 730 735

Glu Glu Thr Lys Lys Tyr Gly Arg Thr Ile Ile Gly Tyr Phe Glu His  
 740 745 750

Tyr Leu Gln Trp Ile Glu Phe Ser Ile Ser Glu Lys Val Ala Ser Cys  
 755 760 765

Lys Pro Val Ala Thr Ala Leu Asp Thr Ala Val Asp Val Phe Leu Cys  
 770 775 780

Ser Tyr Ile Ile Asp Pro Leu Asn Leu Phe Trp Phe Gly Ile Gly Lys  
 785 790 795 800

Ala Thr Val Phe Leu Leu Pro Ala Leu Ile Phe Ala Val Lys Leu Ala  
 805 810 815

Lys Tyr Tyr Arg Arg Met Asp Ser Glu Asp Val Tyr Asp Asp Val Glu  
 820 825 830

VIB-034-PCT.ST25.txt

Thr Ile Pro Met Lys Asn Met Glu Asn Gly Asn Asn Gly Tyr His Lys  
835 840 845

Asp His Val Tyr Gly Ile His Asn Pro Val Met Thr Ser Pro Ser Gln  
850 855 860

His  
865

**THIS PAGE BLANK (USPTO)**

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number  
**WO 03/066097 A3**

- (51) International Patent Classification<sup>7</sup>: **C07K 16/28**,  
A61P 43/00, A61K 39/00, 38/17
- (74) Agent: **BRANTS, Johan, Philippe, Emile**; De Clercq,  
Brants & Partners cv, E. Gevaertdreef 10a, B-9830 Sint-  
Martens-Latem (BE).
- (21) International Application Number: **PCT/EP03/01229**
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 7 February 2003 (07.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
02075544.3 8 February 2002 (08.02.2002) EP  
02077742.1 9 July 2002 (09.07.2002) EP  
03100148.0 24 January 2003 (24.01.2003) EP
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,  
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants (*for all designated States except US*):  
**VLAAMS INTERUNIVERSITAIR INSTITUUT  
VOOR BIOTECHNOLOGIE VZW** [BE/BE]; Rijkss-  
chestraat 120, B-9052 Zwijnaarde (BE). **D. COLLEN  
RESEARCH FOUNDATION VZW** [BE/BE]; Onder-  
wijs & Navorsing, Campus Gasthuisberg, K.U. Leuven,  
Herestraat 49, B-3000 Leuven (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **CARMELIET,**  
**Peter** [BE/BE]; Sappelenbos 10, B-3052 Blanden (BE).  
**MOONS, Lieve** [BE/BE]; Beningsstraat 25, B-2230  
Herselt (BE).
- Published:**  
— *with international search report*  
— *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments*
- (88) Date of publication of the international search report:  
24 December 2003
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: A NOVEL TARGET TO INHIBIT ANGIOGENESIS

(57) Abstract: The invention relates to the field of angiogenesis. In particular the invention relates to the use of molecules binding to prominin-1 that can be used for the manufacture of a medicament to prevent pathological angiogenesis.

WO 03/066097 A3

**THIS PAGE BLANK (USPTO)**

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/01229

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07K16/28 A61P43/00 A61K39/00 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE, EMBL, SEQUENCE SEARCH

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! 23 March 2001 (2001-03-23) HUMAN GENOME SCI INC: "Human secreted protein no.3" Database accession no. AAB64995 XP002251074 abstract	1,2
X	& WO 00 75375 A (HUMAN GENOME SCI INC) 14 December 2000 (2000-12-14)  --- -/--	1-3

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

13 August 2003

Date of mailing of the international search report

24/10/2003

Name and mailing address of the ISA  
European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Irion, A

**THIS PAGE BLANK (USPTO)**



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/01229

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online!  23 March 2001 (2001-03-23)  HUMAN GENOME SCI INC: "Gene no.3  associated peptide no.3"  Database accession no. AAB65031  XP002251075  abstract</p>	1,2
X	<p>&amp; WO 00 75375 A (HUMAN GENOME SCI INC)  14 December 2000 (2000-12-14)  ---</p>	1-3
Y	<p>WO 97 41224 A (AMCELL CORP)  6 November 1997 (1997-11-06)  page 6, line 6 -page 7, line 18  page 13, line 8 - line 32  page 19, line 24 -page 22, line 9  ---</p>	1-3
Y	<p>PEICHEV MARIO ET AL: "Expression of  VEGFR-2 and AC133 by circulating human  CD34+ cells identifies a population of  functional endothelial precursors."  BLOOD.,  vol. 95, no. 3,  1 February 2000 (2000-02-01), pages  952-958, XP002251073  ISSN: 0006-4971  the whole document  -----</p>	1-3

THIS PAGE BLANK (USPTO)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 03/01229

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claim 3 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-2  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-2

Present claims 1-2 relate to a product/compound defined by reference to a desirable characteristic or property, namely the inhibition of the expression and/or activity of prominin-1.

The claims cover all products/compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products/compounds/methods/apparatus. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product/compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products/compounds being

1. antibodies against prominin-1
  2. anti-sense nucleic acids being based on the prominin-1 sequence
  3. short interference RNA being based on the prominin-1 sequence
  4. peptides being based on the prominin-1 sequence
- as indicated on p. 4 l. 10 - 7 l. 2 of the present application.

\*\*\*\*\*

Present claims 1-2 relate to an extremely large number of possible compounds/products. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/products claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds/products

being

1. an anti-prominin-1 antibody,
  2. anti-sense nucleic acids being based on the prominin-1 sequence
  3. short interference RNA being based on the prominin-1 sequence
  4. peptides being based on the prominin-1 sequence
- as indicated on p. 4 l. 10 - 7 l. 2 of the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is

THIS PAGE BLANK (USPTO)

**FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210**

the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

THIS PAGE BLANK (USPTO)



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/01229

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0075375	A	14-12-2000	AU 5458300 A	28-12-2000
			CA 2383828 A1	14-12-2000
			EP 1206573 A1	22-05-2002
			JP 2003501072 T	14-01-2003
			WO 0075375 A1	14-12-2000
			US 2002183503 A1	05-12-2002
			US 2002028449 A1	07-03-2002
WO 9741224	A	06-11-1997	US 5843633 A	01-12-1998
			US 6455678 B1	24-09-2002
			AU 720938 B2	15-06-2000
			AU 2682197 A	19-11-1997
			CA 2251604 A1	06-11-1997
			EP 0953046 A1	03-11-1999
			JP 2000509277 T	25-07-2000
			WO 9741224 A1	06-11-1997
			US 2001051372 A1	13-12-2001

THIS PAGE BLANK (USPTO)